Stratagene's Profits up 25 Percent in Q1 on Steady Sales | GenomeWeb
NEW YORK (GenomeWeb News) - Stratagene yesterday said first-quarter revenues were steady as R&D spending dipped nearly 10 percent and profit increased 25 percent.
 
Total receipts for the three months ended March 31, 2007, rose slightly to $24.4 million from $24.3 million year over year.
 
R&D spending fell slightly to $3.1 million from $3.4 million.
 
The company said net income rose to $1.4 million from $1.1 million in the year-ago period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.